Young-onset dementia—dementia that begins before age 65—can be treated, but no single treatment works for every cause. Most neurodegenerative forms cannot be cured, although some therapies may slow early Alzheimer's or ease symptoms. "Young-onset" describes timing, not a specific disease. Treatment depends on whether the cause is Alzheimer's, frontotemporal dementia, a metabolic disorder, or another condition.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why the exact cause matters
- Treatments for young-onset Alzheimer's
- Who may qualify for anti-amyloid treatment?
- Risks and limits of anti-amyloid drugs
- What can be done when disease cannot be slowed?
Why the exact cause matters
Some metabolic disorders can produce dementia symptoms that may stop or reverse when treated early, according to MedlinePlus. This makes a specialist evaluation important before assuming the symptoms reflect an irreversible neurodegenerative disease. Other causes have much stricter treatment limits.
Frontotemporal dementia commonly affects working-age adults, but no treatment has been proven to slow or stop its progression, according to the National Institute on Aging. A treatment for one cause should not be generalized to another. An Alzheimer's drug does not treat frontotemporal dementia, and temporary symptom improvement does not necessarily mean the underlying disease has slowed.
Treatments for young-onset Alzheimer's
Alzheimer's beginning before age 65 has no cure. Fewer than 10% of people with Alzheimer's develop symptoms this early, and 10–15% of those cases are linked to APP, PSEN1, or PSEN2 variants. Cholinesterase inhibitors and memantine may temporarily support cognition, behavior, or daily function.
They do not reliably halt progression, so their benefit should be judged by changes in symptoms and everyday abilities. Lecanemab, sold as Leqembi, and donanemab, sold as Kisunla, offer a different approach. These anti-amyloid drugs can slow clinical decline in selected adults with early Alzheimer's and confirmed amyloid pathology, but they do not cure the disease.
Who may qualify for anti-amyloid treatment?
Leqembi was studied in people with amyloid-confirmed mild cognitive impairment or mild Alzheimer's dementia. Participants declined less over 18 months than those receiving placebo, but the FDA says effectiveness and safety are unestablished when treatment begins earlier or later than those stages, as explained in its Leqembi approval notice.
Kisunla also reduced decline compared with placebo in amyloid-confirmed early Alzheimer's. However, trial participants were ages 59–86, with an average age of 73, so direct evidence for younger adults remains limited, according to the FDA's Kisunla notice. Before considering either drug, clinicians must determine:.
- Whether the diagnosis is Alzheimer's rather than another dementia
- Whether amyloid pathology has been confirmed
- Whether the person is in the early stage studied
- Whether the expected slowing is worth the treatment risks and monitoring
Risks and limits of anti-amyloid drugs
Anti-amyloid treatment can cause amyloid-related imaging abnormalities, known as ARIA. These abnormalities involve brain swelling or bleeding visible on imaging and can sometimes be serious or fatal. Risk assessment and MRI monitoring are therefore part of treatment.
The risk is higher in people with two copies of the APOE ε4 variant, as detailed in the FDA-approved Leqembi prescribing information. Even when treatment is appropriate, "slowing decline" is not the same as restoring lost abilities or stopping Alzheimer's. The decision requires weighing a limited potential benefit against ARIA risk, monitoring demands, disease stage, and the limited younger-adult trial evidence.
What can be done when disease cannot be slowed?
For frontotemporal dementia, clinicians may use SSRIs or low-dose antipsychotics for selected behavioral symptoms. Speech, physical, and occupational therapy can also address communication, movement, and everyday function, although none alters the underlying neurodegeneration.
A practical evaluation should establish the cause and stage before treatment decisions are made. Ask the specialist whether a treatable metabolic disorder has been considered, whether amyloid confirmation is needed, and what symptom-directed therapies match the person's current difficulties. If anti-amyloid treatment is proposed, ask how eligibility was established, what benefit is realistic, how APOE ε4 affects risk, and when MRI monitoring will occur.
